Clinical Trial Update: Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating ruxolitinib for Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS); the study is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) | Phase 1 | Status: NOT_YET_RECRUITING